Inclisiran – Medxy AI

Evolution and Future Frontiers of PCSK9 Inhibition: From Genetic Discovery to Genomic Medicine

By MedXY 03/25/2026

This review synthesizes the trajectory of PCSK9 inhibitors, from pivotal monoclonal antibody trials to emerging RNA interference and gene-editing technologies, emphasizing their role in achieving ultra-low LDL-C levels and reducing major adverse cardiovascular events.

Cardiology news Pediatrics

Twice-Yearly Inclisiran Transforms LDL-C Management in Adolescents with HeFH: Insights from ORION-16

By MedXY 03/10/2026

The ORION-16 trial demonstrates that inclisiran, a twice-yearly siRNA therapy, significantly and safely reduces LDL cholesterol in adolescents with heterozygous familial hypercholesterolaemia, offering a promising solution for long-term adherence and cardiovascular risk reduction in this high-risk pediatric population.

Cardiology news Pediatrics

Twice-Yearly Inclisiran Successfully Lowers LDL-C in Adolescents with Heterozygous Familial Hypercholesterolaemia: Insights from ORION-16

By MedXY 02/24/2026

The ORION-16 trial demonstrates that inclisiran, a twice-yearly siRNA therapy, significantly and safely reduces LDL cholesterol in adolescents with HeFH, offering a potent new tool for early cardiovascular risk management in high-risk pediatric populations.

Cardiology Specialties

Inclisiran Shows Promise for Adolescents with Homozygous Familial Hypercholesterolemia: Results from the ORION-13 Trial

By MedXY 08/17/2025

The ORION-13 trial demonstrates that inclisiran significantly lowers LDL cholesterol by 33.3% and is safe and well tolerated in adolescents with homozygous familial hypercholesterolemia, addressing an unmet pediatric treatment need.